Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1224626
PUBLISHER: Grand View Research | PRODUCT CODE: 1224626
U.S. Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical/Drugs, Surgery, Photodynamic Therapy), By Drug Class, By Product, By End-use, And Segment Forecasts, 2023 - 2030
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Actinic Keratosis Treatment Market Growth & Trends:
The U.S. actinic keratosis treatment market size is expected to reach USD 2.94 billion by 2030, expanding at a CAGR of 3.03% over the forecast period, according to a new report by Grand View Research, Inc. The wide availability of actinic keratosis therapeutic services and the surge in awareness for actinic keratosis (AK) treatment are anticipated to drive market growth. Moreover, the strong demand for minimally invasive therapies for AK and escalated adoption of topical regimens are expected to support market growth. For instance, according to the National Institute for Health and Care Research, 5% fluorouracil cream is the most preferred and best first-line treatment for actinic keratosis.
The growing consumer awareness about dermatological diseases, such as AK, is a major growth booster for the market. An increase in knowledge about diagnostics and treatment strategies for the disease has driven the overall adoption of AK treatment. Field-directed treatments, such as 5-fluorouracil, diclofenac, and imiquimod are expected to witness greater market penetration over the coming years. For instance, clinical trials demonstrated that the patients treated with imiquimod-containing formulation achieved a clearance of around 75%.
Moreover, higher safety and tolerability factors associated with topical actinic keratosis preparations have increased the demand for topical drugs to treat actinic keratosis. For instance, according to phase-3 clinical trials of topical agents for AK published at clinicaltrials.gov, no severe adverse effects were noted from topical AK therapies. Some formulations produced some local skin irritations like allergies but novel topical preparations such as tirbanibulin, and ingenol mebutate showed more favorable tolerability profiles, which is expected to increase the market growth.
According to the NIH, the combination of photodynamic therapy with topical formulations improves the clearance rates as compared to monotherapy alone. Moreover, according to the study published in Healio, the combination therapy of aminolevulinic acid 20% and PDT has shown positive outcomes with fewer side effects in AK. Thus, a strong promise from combination therapies in the treatment of actinic keratosis is anticipated to propel the market growth during the forecast period.
Moreover, leading participants are undertaking strategic initiatives such as product launches, expansion, and partnerships among other strategies to increase their market share. For instance, in February 2021 Athenex, Inc. a leading biopharmaceutical company launched Klisyri for the treatment of actinic keratosis of the scalp in the U.S. Along with this launch, the company announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia Corp.
U.S. Actinic Keratosis Treatment Market Report Highlights:
- The surgery segment held the largest share owing to the higher demand for complete disease eradication and high penetration of cryotherapy procedures
- The photodynamic therapy segment registered the fastest growth rate because of high site specificity and less incidence of side effects
- The nucleoside metabolic inhibitors segment accounted for the largest market in 2022 due to the strong commercial performance of Fluroplex, Carac, and Efudex along with a higher demand for topical formulations to treat the initial stages of the disease
- Based on product, the 5-fluorouracil segment dominated the U.S. actinic keratosis treatment market in 2022, whereas, the tirbanibulin segment is anticipated to be the fastest-growing segment
- The hospitals segment was the largest in 2022 owing to increasing physician-assisted procedures performed in hospitals
- Key players dominating the market include Bausch Health Companies, Inc.; LEO Pharma A/S; Almirall, S.A.; and Biofrontera AG
Product Code: GVR-4-68040-027-1
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation and Scope
- 1.1.1 Segment scope
- 1.1.2 Regional scope
- 1.1.3 Estimates and forecast timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased database:
- 1.3.2 GVR's internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
- 1.4 Information or Data Analysis
- 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach: Commodity Flow Approach
- 1.6.1 Commodity Flow Analysis
- 1.7 Research Assumptions
- 1.8 List of Secondary Sources
- 1.9 List of Abbreviations
- 1.10 Objectives
- 1.10.1 Objective 1
- 1.10.2 Objective 2
- 1.10.3 Objective 3
- 1.10.4 Objective 4
Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Competitive Insights
Chapter 3 U.S. Actinic Keratosis Treatment Market Variables, Trends, & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent market
- 3.2 Market Dynamics
- 3.2.1 Market drivers analysis
- 3.2.1.1 Increasing disease prevalence
- 3.2.1.2 Preventive strategies
- 3.2.1.3 Easy availability of treatment
- 3.2.2 Market restraint analysis
- 3.2.2.1 Lack of consumer awareness
- 3.2.2.2 Generic penetration
- 3.2.1 Market drivers analysis
- 3.3 Penetration & Growth Prospect Mapping
- 3.4 Influenza Vaccine: Market Analysis Tools
- 3.4.1 Industry analysis - Porter's
- 3.4.2 PESTLE analysis
- 3.5 Regulatory Framework
- 3.6 Pricing Analysis
Chapter 4 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Therapy, 2018 - 2030 (USD Million)
- 4.1 Definition and Scope
- 4.2 Therapy Market Share Analysis, 2022 & 2030
- 4.3 Segment Dashboard
- 4.4 U.S. Actinic Keratosis Treatment Market, by Therapy, 2018 to 2030
- 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 4.5.1 Topical/Drugs
- 4.5.1.1 Topical/Drugs market estimates and forecast, 2018 - 2030 (USD Million)
- 4.5.2 Surgery
- 4.5.2.1 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
- 4.5.2.2 Cryotherapy
- 4.5.2.2.1 Cryotherapy market estimates and forecast, 2018 - 2030 (USD Million)
- 4.5.2.3 Others
- 4.5.2.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
- 4.5.3 Photodynamic Therapy
- 4.5.3.1 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)
- 4.5.1 Topical/Drugs
Chapter 5 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Product 2018 - 2030 (USD Million) (Volume, Number of Units Sold)
- 5.1 Definition and Scope
- 5.2 Product Market Share Analysis, 2022 & 2030
- 5.3 Segment Dashboard
- 5.4 U.S. Actinic Keratosis Treatment Market, by Product, 2018 to 2030
- 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 5.5.1 5-fluorouracil
- 5.5.1.1 5-fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.1.2 Carac
- 5.5.1.2.1 Carac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.1.3 Fluoroplex
- 5.5.1.3.1 Fluoroplex market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.1.4 Actikerall
- 5.5.1.4.1 Actikerall market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.1.5 Tolak
- 5.5.1.5.1 Tolak market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.1.6 Others
- 5.5.1.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.2 Diclofenac
- 5.5.2.1 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.2.2 Solaraze
- 5.5.2.2.1 Solaraze market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.2.3 Voltaren
- 5.5.2.3.1 Voltaren market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.2.4 Pennsaid
- 5.5.2.4.1 Pennsaid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.2.5 Others
- 5.5.2.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.3 Imiquimod
- 5.5.3.1 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.3.2 Aldara
- 5.5.3.2.1 Aldara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.3.3 Zyclara
- 5.5.3.3.1 Zyclara market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.3.4 Others
- 5.5.3.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.4 Tirbanibulin
- 5.5.4.1 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.5 Capecitabine
- 5.5.5.1 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.5.2 Xeloda
- 5.5.5.2.1 Xeloda market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.5.3 Others
- 5.5.5.3.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.6 Aminolevulinic acid
- 5.5.6.1 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.6.2 Ameluz
- 5.5.6.2.1 Ameluz market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.6.3 Levulan
- 5.5.6.3.1 Levulan market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.7 Porfimer sodium
- 5.5.7.1 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.8 Others
- 5.5.8.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.8.2 Gemzar
- 5.5.8.2.1 Gemzar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.8.3 Clolar
- 5.5.8.3.1 Clolar market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.8.4 Vidaza
- 5.5.8.4.1 Vidaza market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.8.5 Metvix
- 5.5.8.5.1 Metvix market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.8.6 Others
- 5.5.8.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million) (Number of Units Sold)
- 5.5.1 5-fluorouracil
Chapter 6 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
- 6.1 Definition and Scope
- 6.2 Drug Class Market Share Analysis, 2022 & 2030
- 6.3 Segment Dashboard
- 6.4 U.S. Actinic Keratosis Treatment Market, by Drug Class, 2018 to 2030
- 6.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 6.5.1 Nucleoside metabolic inhibitors
- 6.5.1.1 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
- 6.5.2 Nonsteroidal anti-inflammatory drugs
- 6.5.2.1 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
- 6.5.3 Immune response modifiers
- 6.5.3.1 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
- 6.5.4 Photoenhancers
- 6.5.4.1 Photoenhancers market estimates and forecast, 2018 - 2030 (USD Million)
- 6.5.5 Others
- 6.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
- 6.5.1 Nucleoside metabolic inhibitors
Chapter 7 U.S. Actinic Keratosis Treatment Market Segment Analysis, By End-use, 2018 - 2030 (USD Million)
- 7.1 Definition and Scope
- 7.2 End-use Market Share Analysis, 2022 & 2030
- 7.3 Segment Dashboard
- 7.4 U.S. Actinic Keratosis Treatment Market, by End-use, 2018 to 2030
- 7.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
- 7.5.1 Hospitals
- 7.5.1.1 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.2 Private clinics
- 7.5.2.1 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.3 Homecare
- 7.5.3.1 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.4 Others
- 7.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.1 Hospitals
Chapter 8 U.S. Actinic Keratosis Treatment Market Segment Analysis, By Region, 2018 - 2030 (USD Million)
- 8.1 Definition & Scope
- 8.2 Regional Market Share Analysis, 2022 & 2030
- 8.3 Regional Market Dashboard
- 8.4 Regional Market Snapshot
- 8.5 SWOT Analysis
- 8.6 Market Size, & Forecasts, Revenue and Trend Analysis, 2022 to 2030
- 8.6.1 U.S.
- 8.6.1.1 U.S. actinic keratosis treatment market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.1.2 U.S.
- 8.6.1.2.1 Key Country Dynamics
- 8.6.1.2.2 Competitive Scenario
- 8.6.1.2.3 Regulatory Framework
- 8.6.1.2.4 Reimbursement Scenario
- 8.6.1 U.S.
Chapter 9 U.S. Actinic Keratosis Treatment Market - Competitive Analysis
- 9.1 Recent Developments & Impact Analysis, by Key Market Participants
- 9.1.1 Ansoff matrix
- 9.1.2 Heat map analysis
- 9.1.3 Major Deals and Strategic Alliances Analysis
- 9.1.3.1 Joint Ventures
- 9.1.3.2 Licensing Agreements
- 9.1.3.3 Product Launches
- 9.1.3.1 Conferences and Campaigns
- 9.2 Company Categorization
- 9.2.1 Innovators
- 9.2.2 Market Leaders
- 9.3 Vendor Landscape
- 9.3.1 List of key distributors and channel partners
- 9.3.2 Key customers
- 9.4 Public Companies
- 9.4.1 Competitive Dashboard Analysis
- 9.4.1.1 Market Differentiators
- 9.4.1 Competitive Dashboard Analysis
- 9.5 Private Companies
- 9.5.1 List of key emerging companies
- 9.6 Company Profiles
- 9.6.1 Bausch Health Companies, Inc
- 9.6.1.1 Company overview
- 9.6.1.2 Financial performance
- 9.6.1.3 Product benchmarking
- 9.6.1.4 Strategic Initiatives
- 9.6.2 LEO Pharma A/S
- 9.6.2.1 Company overview
- 9.6.2.2 Financial performance
- 9.6.2.3 Product benchmarking
- 9.6.2.4 Strategic Initiatives
- 9.6.3 Almirall, S.A
- 9.6.3.1 Company overview
- 9.6.3.2 Financial performance
- 9.6.3.3 Product benchmarking
- 9.6.3.4 Strategic Initiatives
- 9.6.4 Biofrontera AG
- 9.6.4.1 Company overview
- 9.6.4.2 Financial performance
- 9.6.4.3 Product benchmarking
- 9.6.4.4 Strategic Initiatives
- 9.6.5 GALDERMA
- 9.6.5.1 Company overview
- 9.6.5.2 Financial performance
- 9.6.5.3 Product benchmarking
- 9.6.5.4 Strategic Initiatives
- 9.6.6 Sun Pharmaceutical Industries Ltd
- 9.6.6.1 Company overview
- 9.6.6.2 Financial performance
- 9.6.6.3 Product benchmarking
- 9.6.6.4 Strategic Initiatives
- 9.6.7 Novartis AG
- 9.6.7.1 Company overview
- 9.6.7.2 Financial performance
- 9.6.7.3 Product benchmarking
- 9.6.7.4 Strategic initiatives
- 9.6.8 Hill Dermaceuticals, Inc
- 9.6.8.1 Company overview
- 9.6.8.2 Financial performance
- 9.6.8.3 Product benchmarking
- 9.6.8.4 Strategic initiatives
- 9.6.9 Viatris Inc.
- 9.6.9.1 Company overview
- 9.6.9.2 Financial performance
- 9.6.9.3 Product benchmarking
- 9.6.9.4 Strategic initiatives
- 9.6.10 3M
- 9.6.10.1 Company overview
- 9.6.10.2 Financial performance
- 9.6.10.3 Product benchmarking
- 9.6.10.4 Strategic initiatives
- 9.6.1 Bausch Health Companies, Inc
Product Code: GVR-4-68040-027-1
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 Leading market players anticipated to witness the highest growth
- Table 4 U.S. actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
- Table 5 U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
- Table 6 U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
- Table 7 U.S. actinic keratosis treatment market, by product, 2018 - 2030 (USD Million) (number of units sold)
- Table 8 U.S. actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
- Table 9 Product pipeline
- Table 10 Regulatory framework
- Table 11 Comparative study of brands available for diclofenac
- Table 12 Comparative study of brands available for 5-Fluorouracil
- Table 13 Comparative study of brands available for Imiquimod
- Table 14 Treatments currently available for management of AK
- Table 15 Comparative study of brands available for 5-Fluorouracil
- Table 16 Comparative study of brands available for diclofenac
- Table 17 Comparative study of brands available for Imiquimod
- Table 18 Comparative study of brands available for Tirbanibulin
- Table 19 Comparative study of brands available for Capecitabine
- Table 20 Comparative study of brands available for Aminolevulinic acid
- Table 21 Comparative study of brand available for Porfimer sodium
- Table 22 Comparative study of brands available under others segment
- Table 23 Key topical products for actinic keratosis, 2022
- Table 24 Key surgical procedures for actinic keratosis, 2022
- Table 25 Key photodynamic therapeutics for actinic keratosis, 2022
- Table 26 Key nucleoside metabolic inhibitors for actinic keratosis
- Table 27 Key NSAIDs for actinic keratosis
- Table 28 Key immune response modifiers for actinic keratosis
- Table 29 Key photo enhancers for actinic keratosis
- Table 30 Other drug classes for actinic keratosis
- Table 31 Key physician-managed treatment for actinic keratosis
- Table 32 Key home-based treatment for actinic keratosis
- Table 33 Leading market players anticipated to witness the highest growth
- Table 34 Key companies undergoing expansions
- Table 35 Key companies undertaking acquisitions
- Table 36 Key companies undergoing collaborations
- Table 37 Key companies launching new products/services
- Table 38 Key companies undergoing other strategies
List of Figures
- Fig. 1 U.S. actinic keratosis treatment market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Market snapshot
- Fig. 10 Segment snapshot
- Fig. 11 Segment snapshot
- Fig. 12 Competitive landscape snapshot
- Fig. 13 Penetration & growth prospect mapping
- Fig. 14 Consumer behavior analysis
- Fig. 15 Market driver relevance analysis (Current & future impact)
- Fig. 16 Market restraint relevance analysis (Current & future impact)
- Fig. 17 Porter's five forces analysis
- Fig. 18 PESTLE analysis
- Fig. 19 U.S. actinic keratosis treatment market: Product outlook and key takeaways
- Fig. 20 U.S. actinic keratosis treatment market: Product movement analysis
- Fig. 21 Product segment dashboard
- Fig. 22 5-Fluorouracil market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 23 Diclofenac market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 24 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 25 Tirbanibulin market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 26 Capecitabine market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 27 Aminolevulinic acid market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 28 Porfimer sodium market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million) (Volume Unit sold)
- Fig. 30 U.S. actinic keratosis treatment market: Therapy outlook and key takeaways
- Fig. 31 U.S. actinic keratosis treatment market: Therapy movement analysis
- Fig. 32 Therapy segment dashboard
- Fig. 33 Topical market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 34 Surgery market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 35 Photodynamic therapy market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 36 U.S. actinic keratosis treatment market: Drug class outlook and key takeaways
- Fig. 37 U.S. actinic keratosis treatment market: Drug class movement analysis
- Fig. 38 Drug class segment dashboard
- Fig. 39 Nucleoside metabolic inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 40 Nonsteroidal anti-inflammatory drugs market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 41 Immune response modifiers market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 42 Photo enhancers market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 44 U.S. actinic keratosis treatment market: End-use outlook and key takeaways
- Fig. 45 U.S. actinic keratosis treatment market: End-use movement analysis
- Fig. 46 End-use segment dashboard
- Fig. 47 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 48 Private clinics market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 49 Homecare market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 51 Key country dynamics
- Fig. 52 U.S. actinic keratosis market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 53 Ansoff Matrix
- Fig. 54 Heat map analysis
- Fig. 55 Market differentiators
- Fig. 56 Market participant categorization
- Fig. 57 U.S. actinic keratosis treatment market share analysis, 2022
- Fig. 58 Strategic framework
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.